Jeroen Hiltermann

Zoekresultaten

• 2025

  Real-world 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable, stage III NSCLC: Final data extraction from PACIFIC-R

  Girard, N., Bar, J., Daniel, C., Field, J., Fietkau, R., Garassino, M. C., Lopez, P. G., Haakensen, V. D., Hiltermann, J. T., Kao, S. C., McDonald, F., Mornex, F., Moskovitz, M. T., Peters, S., Siva, S., Solomon, B., Qiao, Y., Anand, S., Chander, P. & Filippi, A. R., mrt.-2025.

  Onderzoeksoutput › Academic